MyChesCo on MSN14h
NCCN Funds Research to Address Side Effects of PARP Inhibitors in Prostate Cancer Treatment
The National Comprehensive Cancer Network® (NCCN®) Oncology Research Program (ORP) has announced funding for a new project ...
Medscape17h
Radiotherapy in the Management of Prostate Cancer After Radical Prostatectomy
For some patients, important quality-of-life parameters, general age-related conditions, the cancer diagnosis and surgery have a stronger impact than radiotherapy (RT). In clinical trials subgroup ...
Medscape17h
Maximizing Survival in Metastatic Castrate-resistant Prostate Cancer
The author's clinical experience with cabazitaxel is documented later in the section entitled 'Cabazitaxel: clinical experience at Rosemere Cancer Centre'. NR: Not recorded; PSA: Prostate-specific ...
pharmaphorum17h
Five takeaways from the new donanemab data
Headlines about the results of TRAILBLAZER-ALZ2 trial of Eli Lilly’s Alzheimer’s drug candidate donanemab are spreading around the world, with some going as far as to suggest this could herald ...